Drug intelligence / Profile preview

Respicure

Development stage: Preclinical
Lead developer: Beker Laboratories
Modality: Small Molecules
Administration: Inhalation

Overview

Respicure is an inhalation solution developed by BEKER Laboratories. It is a phytotherapy product containing two natural extracts, resveratrol and quercetin, each at a concentration of 0.38%. It is being evaluated as an add-on treatment in the management of various respiratory conditions, including partially controlled asthma, Chronic Obstructive Pulmonary Disease (COPD) across all stages (A, B, C, and D), and long COVID in Algerian adult patients.

Brand names: Respicure

Beyond the preview

Go deeper on Respicure.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Respicure.

Explore the full profile